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The systematic review and meta-analysis by Kakkos et al.1
highlights the non-inferior outcomes and safety of new
oral anticoagulants (NOAs) used in venous thromboembo-
lism (VTE) compared with conventional treatment with
vitamin K antagonists (VKAs). However, there are few areas
that remain unsettled and further analysis of the existing
trials may be needed.
The results could possibly be different if cost-
effectiveness and quality of life were analyzed. Although
the authors mentioned the presence of cost-effectiveness
studies of NOAs used to treat VTE,2,3 such analysis has
not been provided in this meta-analysis to assess the coste
beneﬁt ratio. One could reasonably argue that this issue
could have an important impact, similar to that of the cost-
effectiveness of NOAs versus VKAs, on the treatment of
atrial ﬁbrillation.4
Quality of life assessments of oral anticoagulants have been
attracting interest since as early as in 1991.5 As such, a speciﬁc
instrument has been developed and validated.6 Therefore,
the inclusion of lifetime quality adjusted life years and cost of
NOAs compared with VKAs as additional outcomes should be
assessed in previous and future clinical trials.
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We would like to thank the authors of this letter for giving
us the opportunity to discuss further the value of the new
oral anticoagulants (NOAs) in the management of venous
thromboembolism (VTE), which was the subject of a meta-
analysis recently published in the European Journal of
Vascular and Endovascular Surgery.
Several areas remain unsettled, and further analysis of the
existing trials may provide additional information on the ef-
ﬁcacy and safety in predeﬁned subgroups of the trials,
although this process will limit the power of the analysis.
Assessment of cost-effectiveness requires speciﬁc method-
ology, and was not the purpose of the investigation. This is
usually a stand-alone study based on the results of the
original studies. However, it is agreed that cost-effectiveness
studies should be performed, particularly in the secondary
prevention of VTE, where an improved patient survival with
the NOAs compared with placebo was evident from this
meta-analysis. Likewise, the reduced bleeding rate with the
NOAs compared with warfarin in VTE treatment is expected
to tip the balance in favour of the former. Ideally, cost-
effectiveness studies also should be carried out for each
NOA separately, because of the different properties of these
agents. Secondary prevention studies comparing the NOAs
with warfarin head-to-head in patients with unprovoked VTE
are scarce (RE-SONATE trial), and could be performed to
354 Correspondenceinform clinicians and patients, ﬁrst, of the long-term risk of
bleeding, anticipated to be reduced with the formal agents,
and, second, on the relative frequency of the post-
thrombotic syndrome; the latter is a cause of impaired
quality of life and has been shown to be reduced with the use
of tinzaparin compared with vitamin K antagonists, but the
evidence for NOAs is lacking. Finally, quality of life was not
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We read with interest the recent article by Mestres et al.1
and would like to congratulate our colleagues on such a
high number of cases. In our recent review we found only
23 cases reported between 1951 to 2014.2 The authors
conclude that bypass remains a safe and effective option.1
Given the fact that donor artery aneurysm formation is
the result of long-term (10e15 years from the time of
construction) pathophysiological processes, bypass might
be a safe but not necessarily the best long-term solution.1e3
Firstly, recognition of a “non-affected arterial section” by
chronic aneurysmal degeneration for the proximal and
distal landing zone of the bypass remains difﬁcult. Secondly,
the majority of these patients present with pain as a
consequence of compression of nerves, veins, and/or local
tissue, thus a complete resection and end to end grafting
might be more effective in alleviating symptoms and
restoring ﬂow.2 Thirdly, aneurysmectomy followed by
interposition grafting (vein, PTFE, and composite) tends to
maintain more of the natural anatomy thus reducing the
susceptibility of the new bypass to trauma, kinking and/or
compression.2 Finally, only one case (n ¼ 1) in the series
(n ¼ 12) was treated by aneurysmectomy and therefore the
authors have not provided adequate numbers for compar-
ison of long-term outcomes among the two surgical mo-
dalities of exclusion and bypass versus aneurysm resection
and interposition grafting.1
Overall, we acknowledge that such cases pose a signiﬁ-
cant challenge both in detection and surgical correction.
With the longer duration of AVF in combination withprolonged life, it is perhaps no surprise that we are wit-
nessing more of these “inﬂow aneurysmal degenerations”
that were once rare in clinical practice.
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Thank you for your comments. As you suggest, aneurysmal
degeneration of the inﬂow artery is not a common
complication after AVF, but its frequency will probably rise
as the life expectancy of patients improves.
Responding to your comments, ﬁrstly, we agree that it
is hard to ﬁnd a safe proximal and distal “non-affected”
artery, so there is a risk of proximal or distal aneurysmal
degeneration (as described in our series), but this is not
common. Thus, autogenous bypass remains safe, and is
the most effective treatment option, even if complications
